Experts warn caffeine pouches are the latest stimulant aimed at teens
'Yes, guys, you can literally pregame recess with these,' the video creator says, holding up a tin of LyvWel 'Cherry Blast' caffeine pouches.
There are a lot of similar videos all over TikTok.
'Can a 13-year-old use or buy upper-deckies from the TikTok shop? Yeah, of course you can,' a different user said, referencing the popular online nickname for pouch products. 'These are literally just caffeine pouches.'
There is no national age restriction on caffeine in the U.S., so anyone can purchase products that contain the stimulant. Caffeine use in kids can even result in a hospital trip, which is rare but on the rise. The number of children ages 11 to 14 who had to visit the emergency room due to a caffeine overdose doubled between 2017 and 2023, according to a November 2024 study.
And experts are getting increasingly concerned about the impact of caffeine on children, and the marketing tactics that could expose kids to these products.
Dr. Michael Garcia, an internal medicine doctor with a focus on nutrition at UCLA Health, told The Independent that 'less is more' when it comes to caffeine for adolescents. Long-term use among teens can increase blood pressure, worsen anxiety and impact sleep, he explained.
'We know caffeine is one of those things our body can develop tolerance to,' Garcia said. 'So little by little, maybe use increases as that tolerance develops. And it's like any other stimulant or substance that gives us some sort of immediate effect, we then depend on it ... long-term.'
The American Academy of Pediatrics suggests 100mg as the upper limit for kids 12-18, which is about the equivalent of a cup of drip coffee, about two cans of Diet Coke, or one energy drink.
There are several other companies that sell caffeine pouches, including Deckiez, Rebel Pouches, and Wip, a caffeine pouch start-up founded by Richard Mumby, a strategic investor and marketing executive who worked with the e-cigarette company Juul.
Different brands have different amounts of caffeine: many of LyvWel's pouches contain 56mg per pouch, which is roughly equivalent to a can of soda. Deckiez sells pouches with 40mg and 50mg of caffeine. Wip sells products with 100mg and 200mg of caffeine per pouch, with 15 pouches per package.
Wip's Instagram features influencers over 18 promoting the products while doing athletic activities, including surfing, skateboarding and weightlifting. Rebel Pouches' Instagram shows men playing golf, softball and running, amongst other sports. Deckiez, founded by a teenager and his father, shows the now-college student founder talking with other young men, and shows people snowboarding and playing softball. LyvWel's focuses on discount prices and flavor variety.
Dr. Robert Jackler, founder of the Stanford Research Into the Impact of Tobacco Advertising group, tells The Independent he's concerned social media marketing tactics could make teens eager to try the products, pointing out Wip's use of sports teens are particularly attracted to.
'These videos of the skateboarder doing his tricks…I mean, there may be 50-year-olds and 30-year-olds who are interested in that, but it clearly has a differential interest amongst young people,' he said.
Dr. Bonnie Halpern-Felsher, a developmental psychologist at Stanford Medicine, also argued that using influencers and sporty imagery indicates it's 'clearly being marketed to young people.'
'You could talk about users on the way to the office, on the way to a business meeting…that would be much more obvious that you're targeting adults,' she said. 'There's nothing that I can see of the sort here. It is all fun and games.'
However, caffeine pouch companies claim that they only aim their products to over-18s and, there's age-related warnings on the tin.
Wip rejects any suggestion that they have advertised to underage children, with the company noting that its packaging is designed to appeal to adults and that hiring influencers is normal marketing practice. The product also includes age and usage recommendations, including a warning that says Wip is intended for people 18 and older.
'Wip has adopted an exceptionally proactive and responsible marketing approach, grounded in and exceeding official health authority guidelines,' the company said in a statement to The Independent.
Deckiez founders Dean and Mike Herkenrath noted that their product was created 'as a healthier alternative to the huge spike in nicotine pouch use' and pointed out that caffeine has some health benefits for adults. For instance, studies have shown that adult coffee drinkers are less likely to develop heart failure, according to Johns Hopkins Medicine.
'Many of our customers have quit or heavily reduced their nicotine pouch consumption and we're very proud of that,' the Herkenraths said in a statement. 'Our social media content is indented for success minded young adults to ageless at heart seeking to energize their goals!'
LyvWel said in a statement to The Independent that the TikTok creators encouraging 13-year-olds to try their caffeine pouches are not affiliated with the company, and appear to be using 'TikTok's Affiliate Program, which allows any user regardless of age to tag and promote TikTok shop products without brand involvement or approval.'
The company says it has tried to report 'several inappropriate videos,' but some haven't been taken down. The Independent has contacted TikTok for comment.
As interest in caffeine pouches grows, Dr. Grace Kong, a psychiatry professor at Yale Medicine who specializes in child and adolescent psychology, told The Independent that adolescents don't have all the tools they need to make informed decisions about caffeinated products, especially those they find on social media.
'There is an issue if we're targeting that kind of advertising or marketing to teens for those substances, because teens are still minors,' she told The Independent. 'There still needs to be protection in some way about the decision-making.'
She noted that she thinks caffeine pouches are too similar in design to nicotine pouches, which could encourage young people to try them. 'It could be a gateway, or it could really normalize pouch use,' Kong said.
There's also concern about how the caffeine is being delivered through these pouches, Dr. Taylor Argo, an adolescent medicine fellow at the University of Michigan, told The Independent.
'There are lots of blood vessels right there, and so that caffeine is being absorbed directly into the bloodstream…we hypothesize that when you put medicines directly into your mouth that way, or other substances, it's absorbed a little faster,' she said.
The 'biggest risk factor' for teens when using high levels of caffeine is irregular heart rates, also known as cardiac arrhythmias, Argo said.
'I actually have not heard of any of my patients using these, and I care for teens every day…I do worry about the amount of caffeine that is in it and how it's being delivered,' she added.
Garcia encourages parents to talk about caffeine products with their teens and learn why they might want to use them.
'I think as adults, we are always inclined to provide a solution, but I think there's a lot of value in listening,' he said.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medical News Today
an hour ago
- Medical News Today
Might a combination of 2 cancer drugs help treat Alzheimer's disease?
Researchers are actively seeking treatments or a cure for Alzheimer's diseaseOne current research avenue is to look at currently-approved medications that are used for other diseases, an approach that is called drug repurposing. A new study has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Researchers all over the world are actively seeking treatments or a cure for Alzheimer's disease — a form of dementia currently impacting about 32 million people globally. The medications used right now for Alzheimer's disease are designed to only help treat symptoms and slow disease progression. One avenue scientists are taking in an effort to find treatments for Alzheimer's disease is by looking at currently-approved medications that are used for other diseases, an approach called drug repurposing. 'The idea of drug repurposing or identifying new uses for existing drugs, can speed up the drug discovery process because the compounds already have been tested for toxicity and adverse events,' Marina Sirota, PhD, professor and interim director of the University of California — San Francisco Bakar Computational Health Sciences Institute explained to Medical News Today.'Alzheimer's disease is a complex disease, which is very difficult to treat so we need to use all the tools possible to speed up drug discovery and help patients,' said SirotaSirota is the co-senior author of a new study recently published in the journal Cellthat has identified two cancer medications that may help overturn brain changes caused by Alzheimer's disease, possibly slowing or even reversing the disease's symptoms. Focusing on cancer drugs letrozole and irinotecanFor this study, researchers began by using past studies to assess how Alzheimer's disease changed gene expression in brain cells, mainly neurons and glia. 'Glia cells are non-neuronal cells that provide support and protection to neurons in the nervous system,' Sirota explained. 'By targeting both neuronal cells and non-neuronal cells (glia) we hope to be able to more comprehensively target disease pathophysiology.' From there, scientists then took the gene expression signatures they found and used a database called the ConnectivityMap, allowing them to examine thousands of drugs to find ones that reversed the Alzheimer's disease gene expression signature.'We started with a set of 1,300 drugs and narrowed it down to the combination of letrozole and irinotecan through data driven analysis using both molecular and clinical data,' Sirota said.'We first identified compounds that reversed the cell type specific disease signatures back to normal based on the gene expression profiles. We then further filtered the list to the candidates that affect several cell types,' she explained.'Then we wanted to see whether patients who are on those drugs already have a lower risk of Alzheimer's disease by querying electronic medical records across the UC system,' she continued. 'This has allowed us to narrow our list down to a handful of drugs and focus on this combination.' The analysis of electronic medical records did indeed show that both drugs were associated with a significantly lower risk of Alzheimer's disease, confirming the of cancer drugs reverses brain cell damage, reduces protein build-up in mouse modelNext, researchers decided to test the combination of letrozole — used to treat breast cancer — and irinotecan — used to treat colorectal and lung cancer — in a mouse model of aggressive Alzheimer's disease. At the study's conclusion, Sirota and her team found that the drug combination overturned multiple aspects of Alzheimer's disease in the mouse model, including undoing the gene expression signature changes in the neurons and glia caused by the disease. Additionally, researchers found the combination cancer drugs helped reduce the amount of amyloid-beta and tau proteins in the brain, which are known hallmarks of Alzheimer's disease. 'This tells us that multiple levels of evidence — molecular data, clinical information and mouse model experiments are all aligning to tell us that these compounds might be helpful for Alzheimer's disease patients,' Sirota further noted that:'While we don't know the exact mechanism of how these drugs work to treat Alzheimer's disease, we know that irinotecan is a chemotherapy drug that works by inhibiting the enzyme DNA topoisomerase I, specifically targeting the S and G2 phases of the cell cycle. Letrozole's mechanism of action involves inhibiting the enzyme aromatase, which is crucial in the biosynthesis of estrogen.''However, we don't know whether it is the main aforementioned mechanisms or off-target effects of these drugs which might help Alzheimer's disease patients,' Sirota cautioned. 'Additional experiments need to be carried out to better understand how these two drugs might work together to combat Alzheimer's disease in patients.'Using 'big data' and inventive approaches to find potential Alzheimer's drug targetsMNT had the opportunity to speak with John Dickson, MD, PhD, a neurologist at Massachusetts General Hospital, about this research. 'This is an interesting and innovative paper that uses 'big data' to aid in identifying potential drug targets to treat Alzheimer's disease and then tests candidates in a preclinical model of Alzheimer's disease,' Dickson, who was not involved in this research, said.'Combining the use of transcriptomic data from brain tissue from Alzheimer's disease patients, drug perturbation studies in cell lines, and patient data from electronic medical records was an inventive approach to identifying and narrowing down potential drug targets,' he Dickson's view, 'the decision to use a dual-therapy approach and plan to target multiple cell types with this strategy was also innovative.''The combination of drugs showed beneficial effects on the memory testing and neuropathological findings in a mouse model of Alzheimer's disease. In addition to identifying two potential candidate therapies for Alzheimer's disease, this paper also provides an experimental paradigm for identifying new drugs to treat a variety of conditions,' he look at repurposing existing drugs for Alzheimer's treatment? MNT also talked to Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA, about this study, who said it is refreshing to see data that supports improving memory loss through a novel mechanism that is not related to current therapies that work on brain acetylcholine, N-methyl-D-aspartate (NMDA), or amyloid.'This study's design is smart and the data is captivating,' Segil, who likewise was not involved in the research, added. 'Repurposing medications already being used has been extremely rewarding in neurologists and I truly hope something grows out of this research.' And Peter Gliebus, MD, neurologist and director of cognitive and behavioral neurology at Marcus Neuroscience Institute, part of Baptist Health South Florida, also not involved in the research, commented to MNT that this was a promising and exciting study, and said that repurposing existing drugs offers several advantages. 'Faster development since these drugs already have established safety profiles, which reduces the time and cost required for clinical trials,' Gliebus noted.'Cost-effectiveness [is achieved] by avoiding the high expenses associated with developing new drugs from scratch. And [this approach has] a broader impact, as many existing drugs may have unexplored mechanisms that could address complex Alzheimer's disease pathologies, such as neuroinflammation, synaptic dysfunction, and metabolic deficits.''Given the high failure rate of Alzheimer's drug trials, repurposing provides a practical and efficient pathway to identify effective treatments,' the neurologist concluded.
BBC News
an hour ago
- BBC News
Daventry MP committed to constituency despite new shadow role
The new shadow health secretary said he is still committed to his constituency describing it as his "bread and butter".Stuart Andrew took on the role in Conservative leader Kemi Badenoch's reshuffle of her senior team last MP for Daventry was previously the shadow culture secretary and a minister in Boris Johnson's he said his work in the constituency was the "part of the job I absolutely love doing. So it's really it's about making sure you put in the hours". Andrew replaced Edward Argar, who stood down following a "health scare".He told BBC Radio Northampton's Annabel Amos that the offer of the role was "quite a surprise"."I'm under no illusions of the enormity of the task I have ahead of me, but it is one that I have quite an interest in. So I'm looking forward to it," he MP said he is "quite used to" juggling constituency work and being in the shadow cabinet."I know that my constituency is my bread and butter if you like, [constituents] are always are a priority for me."I always do what I can to help my constituents when they come and see me asking for my help and go out and about." 'Tricky position' The MP, who represented Pudsey in West Yorkshire from 2010 until the constituency was abolished before the July 2024 election, said he would "work constructively" with Health Secretary Wes Andrew was critical of his handling of the recent strike by resident doctors in England and said the health secretary should have put in guarantees over industrial action when medics were awarded a pay rise last year."The government have got themselves in a really tricky position, and what we need to do is make sure that the patients in this country are getting the care that they need," he has also written to the General Medical Council to say resident doctors should be prevented from British Medical Association (BMA), a trade union for doctors, and the health secretary agreed to resume talks earlier this warned the union it had lost the government's goodwill because of the latest strike, which finished on Wednesday. Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.
The Independent
2 hours ago
- The Independent
‘I don't regret I stopped breastfeeding to take Ozempic. I should have done it sooner'
I remember standing in the bathroom that October morning in 2023, exhausted, staring at the scale. The number – 88kg, or about 13 stone – hit harder than I expected. I wasn't shocked, exactly, but I had been avoiding the scale for months. Something about seeing that number in black and white made it feel official: I didn't look or feel like myself anymore. My maternity clothes were still too tight. My face was fuller, my body unfamiliar. The baby was here, and healthy and I was grateful for that. But I was lost. I'd been through this cycle before. When I became pregnant with my firstborn, Lewis, in early 2019, I weighed around 65kg, or three stone lighter, which is more or less where I'd always been. At 5ft8, that felt like home: a stable, healthy weight where I had a good relationship with food and with myself. I was in my early thirties – young enough to 'snap back' after pregnancy (or so I thought). Yet, I was more preoccupied with it than I imagined – after his beautiful birth (a low-stress C-section since he was breech), one of the first things I did was get on the scale. Yet I was baffled: how does a baby weighing seven pounds result in a loss of only five, I thought? Postpartum, I did drop a few more pounds, eventually to around 77kg or 12 stone, but never below that again. Granted, I didn't diet or exercise particularly aggressively – I'm not built that way – but I stayed stuck. Then, later into my thirties, came Luke, my second son. I stopped looking at the scales midway through. Regardless of the fact that my body was doing this miraculous thing, despite how overjoyed I felt to have two healthy boys, I couldn't prevent the wash of shame – and anxiety, disgust, even – that seeing '15 stone' on my record post-birth provoked. I carried guilt along with the extra weight. Breastfeeding was supposed to be straightforward. According to the thousands – the parenting circles, the health campaigns and comment sections – who religiously repeat the mantra, 'breast is best', and, they'll add, it burns calories! It'll help you lose your pregnancy weight! Yet, that's not exactly a proven theory – and, for so many women, it just doesn't work. Plus, behind the slogans lies a trap of judgment and internal conflict: women face pressure if they can't breastfeed and pressure if they do – especially beyond six months, pressure that is linked with increased postpartum anxiety. The moment that someone stops early, even pain-ridden or supply-stricken mothers, a new wave of judgment from formula-shaming peers, and even loved ones. Couple that shame, then, with the enduring stigma of postpartum weight loss, and with the new judgment du jour – using injectables like Ozempic. Behind closed doors, in hushed voices at the playground, there are plenty of us talking about it both in the US, where I live, and the UK. In fact, I've noticed an increase in women around me using injectables, some to get them back to their pre-pregnancy weight, many of them stopping breastfeeding to do so. Reportedly, though I've never been invited to any myself, there are WhatsApp groups for so-called 'sema[glutide]-mums' – and, though I was able to get mine through my own doctor and work benefits in the States, many end up paying through the nose for it themselves. But, in the end, like me, they had to put their own mental health first. For me, breastfeeding Lewis was agony: I had bleeding nipples, terrifying letdown pain, a baby who fed for ages and still seemed unsatisfied. I alternated between breastfeeding, pumping and formula. When nothing helped, I felt I had failed. When I switched fully to formula, I felt relief and – you guessed it – more shame. With Luke, I tried again: this time I battled low supply, consulted lactation consultants, fixed his tongue‑tie, used nipple shields – but still, nursing felt like torture. I couldn't sleep at night; the obsessive feeding schedule crushed every ounce of mental stability. Two pregnancies and years of disrupted sleep and self-care meant I was stuck. Not just in my body, but in the overwhelming pressure to 'snap back'. The idea that 'bouncing back' – re-emerging with their pre-baby bodies weeks after delivery – is only reinforced by media that praises celebrity mums who manage it, and highlights those who retain their postpartum weight as failures. There's a catch though, as we're now learning: you might be negligent if you remain overweight – but medicating to lose it? Also, not good enough. According to most (admittedly) literature and experts, taking Ozempic while breastfeeding is not recommended – while we know the substance transfers to milk, we don't know the effects that might have on the baby. I knew that, while some people take it alongside nursing their babies, I wouldn't have ever taken that risk. So, by October 2023, I had stopped breastfeeding Luke out of sheer discomfort and in an attempt to regain parts of myself I had lost. My energy was gone. My self-esteem teetered at the edge of collapse. Food noise was intolerable – breastfeeding had left me so hungry, and my hormones were all over the place. I would wake up in the night and eat a whole bag of sweets, or go to McDonald's and compulsively order 20 chicken McNuggets – it was all so out of character and out of control. I thought that taking my ADHD medication again – from which I'd abstained during breastfeeding – might help me shed a few pounds, but when it didn't, I went straight to plan B: Ozempic. I was lucky that I had people around me supporting me, some of whom, like my mother-in-law and a friend, had safely used weight loss injectables themselves. That made the decision seem less shameful. I chose the lowest dose (0.25mg) to begin with, and then doubled it. The shift was magical: within days, food stopped crowding my mind. I wasn't waking at night to binge. My appetite, finally, felt normal and I wasn't having destabilising side effects. My son was thriving on formula – finally happy to have more than enough to eat – and within weeks, I was slipping back into my pre-pregnancy clothes. And the success only continued. By the middle of last year, I was back down to around 10 stone. I'm not skinny – but that was never really my prerogative. More importantly, I felt stable, energetic, and I felt like myself again. I could chase my kids around, feel present and engaged. Ozempic was never laziness or a cop-out – it was medicine that helped me restore a version of myself I'd lost. Of course, the shame still lingers in some circles. There's one friend I know I'd never tell (though I wouldn't lie if she asked). Despite the fact that she's a nurse, she made very strong comments about being 'against' the drugs when I was first going on them (I found it interesting to find out that she took them herself around six months later and lost 10kg). Some friends I've never told because they've never asked, others think I lost the weight another way, oblivious to the internal struggle I had to wage. It's not unusual to be discreet about it – judgment is still rife and, sometimes, you just have to protect your own peace. It's why the 'secret jabbers' (people feeling pressured to hide their Ozempic use) phenomenon is so widespread. Somehow, it's seen as a moral failing of sorts to use it over diet or 'self-control'. As a result, experts are calling for weight-loss medication to be understood as treating a chronic condition, not as a so-called shortcut. I believe that women should be able to make their own informed decisions about their own babies and their own bodies. I don't regret stopping breastfeeding early. I also don't regret taking Ozempic. These choices helped me reclaim my body and my mental health. They gave me energy, restored my confidence, and let me move freely in my life again. The more women who hear this without stigma – that whatever choice you make will be best for you and your baby – the more women who hopefully will avoid spiralling in private shame. Maybe someone will feel more at ease skipping another painful feeding session, or feel brave enough to ask their doctor about weight-loss medication without embarrassment. Ultimately, a cultural shift is needed: less 'fat talk', more celebration of postpartum diversity. Fewer whispers of 'just eat less' and more acceptance of body change – especially the radical transformation that pregnancy and birth prompts – as a part of life. Let's say that freedom from food noise is worthy. Some women might find healing through treadmill miles, others through letting go of milk and allowing a drug to help them reset. That's me and I can say, hand on heart, that it's been nothing short of life-changing for me. Currently, I weigh around 68kg (10.5 stone). I don't feel fat. I don't feel ashamed. I do feel healthy. And I do feel at peace with myself and able to enjoy being a hands-on mum. I'm still trying to find balance – some days I eat better and move my body more than others, but that's OK. I learned that my worth isn't tied to the size of my jeans or anyone else's opinion about that. The only regret I have is not doing it all sooner.
